Castle biosciences inc.

Oct 2001 - Jul 2010 8 years 10 months. I held various positions during my employment. Some of these positions included Team Leader and staff nurse OR, temp purchasing coordinator as well as seats ...Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q1 2022 Results - Earnings Call Transcript. SA Transcripts Mon, May 09, 2022.A list of the latest Castle Biosciences Inc News - CSTL Stock News, Press Releases, Earnings Report, Financial Disclosures, Offerings, Acquisitions.DecisionDx-Melanoma is a validated 31-gene expression profile (GEP) test that was developed to identify the risk of recurrence or metastasis including the likelihood of sentinel lymph node positivity for patients with stage I, II, or III melanoma and inform patient management decisions. The DecisionDx-Melanoma test accurately and independently ...

SEC Filings. Select Year: Filter filing type: Date Filing Type Filing Description Download / View. 11/22/2023. 144/A. Amended report of proposed sale of securities. 11/22/2023. 4. Statement of Changes in Beneficial Ownership.FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET. Company Participants. Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs.

How does it work? - TissueCypher®. Clinicopathologic risk factors like age, sex, obesity, family history and expert pathology have been shown to have limited ability to predict progression to esophageal cancer. TissueCypher outperforms these risk factors and provides physicians with an actionable risk score and the patient’s personalized 5 ...FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will share new ...By providing your email address below, you are providing consent to Castle Biosciences to send you the requested Investor Email Alert updates. * Required. Email Address*. Investor Alert Options*. News. Events & Presentations. Quarterly Reports. Annual Reports. SEC Filings.Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes. Castle Biosciences (NASDAQ:CSTL) has a recorded net income of -$67.14 million. CSTL has generated -$2.84 earnings per share over the last four quarters. What is Castle Biosciences's EPS forecast for next year? Castle Biosciences's earnings are expected to grow from ($3.15) per share to ($3.00) per share in the next year.

2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%) After...

Biosaintifika was established in 2009. Title with the title Biosaintifika Berkala Ilmiah Biologi. Starting from Volume 5 Number 2 September 2013, this journal is only published three …

Now $19 (Was $̶3̶8̶) on Tripadvisor: Rooms Inc Hotel, Semarang. See 316 traveler reviews, 561 candid photos, and great deals for Rooms Inc Hotel, ranked #16 of 300 hotels in …May 2018 - Present5 years 6 months. Baltimore, Maryland Area. 2019 Circle of Excellence Award Winner (178% to goal) 2021- 134.1% to goal. New business development of Castle Biosciences Cancer ...Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q1 2022 Results - Earnings Call Transcript. SA Transcripts Mon, May 09, 2022.Castle Biosciences, Inc. Contacts Investor Contact: Camilla Zuckero 832-835-5158 [email protected] Media Contact: Allison Marshall [email protected] artificial intelligence-based technology, DiffDx-Melanoma provides a high level of accuracy and low technical failure. Validation of the test included a variety of benign and malignant lesions. In the clinical validation study, DiffDx-Melanoma provided a clinically actionable result in greater than 96% of reported cases.5 Castle Biosciences, Inc, 505 S. Friendswood Dr., Ste 400, Friendswood, TX, 77546, USA. [email protected]. PMID: 35216597 PMCID: PMC8876832 DOI: 10.1186/s13000-022-01211-w Abstract Background: To improve identification of patients with cutaneous squamous cell carcinoma (SCC) at high risk for metastatic disease, the …

Founder, President and CEO. Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President, Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated ... Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes.Deciding the frequency and intensity of follow-up and surveillance. DecisionDx-SCC is performed on formalin-fixed, paraffin embedded (FFPE) primary tumor tissue from either a biopsy or excision. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes. View the latest Castle Biosciences Inc. (CSTL) stock price, news, historical charts, analyst ratings and financial information from WSJ. National award recognizes Castle’s strong culture and employee engagement. September 19, 2023 07:00 AM Eastern Daylight Time. FRIENDSWOOD, Texas-- ( BUSINESS WIRE )--Castle Biosciences, Inc ...This Registration Statement on Form S-8 is being filed by Castle Biosciences, Inc. (the “Registrant”) for the purpose of registering (i) an additional 1,327,684 shares of the Registrant’s Common Stock, $0.001 par value per share (“Common Stock”), under the Registrant’s 2019 Equity Incentive Plan (the “2019 Plan”), pursuant to the provisions of …

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ...Alice Izzo has served as our Senior Vice President, Marketing, since April 2022. Ms. Izzo joined Castle in September 2013 as our Executive Director, Marketing, and was promoted to Vice President, Marketing, in March 2018. Prior to joining Castle, Ms. Izzo held various leadership positions at Amylin Pharmaceuticals, including Vice President of ...

Texas - Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication …Mar 1, 2023 · Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago. Castle Biosciences Named a Winner of the 2023 Top Workplaces USA Award for the Second Year! Castle Biosciences Inc. is growing, and we are looking to hire a Pre-Billing Prior Authorization ...PROGNOSTIC AIDS. Once melanoma diagnosis has been established, an innovative molecular assay that can be used to help in the prognosis is the Decision-Dx melanoma gene expression profiling test (Castle Biosciences). Prognosis requires traditional staging and includes looking at parameters like Breslow depth and mitotic …Castle Biosciences Inc’s price is currently down 25.04% so far this month. During the month of October, Castle Biosciences Inc’s stock price has reached a high of $16.84 and a low of $12.07. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26.Castle Biosciences, Inc. 19.85. +0.47. +2.43%. Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences ...

Nov 3, 2022 · Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs

Castle Biosciences is a high growth, commercial stage molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and ...

On April 12, 2023, Castle Biosciences, Inc. (“Castle”) filed a definitive proxy statement (the “Proxy Statement”) with the Securities and Exchange Commission in connection with its 2023 Annual Meeting of Stockholders to be held on May 25, 2023 (the “Annual Meeting”). On May 15, 2023, Castle issued the below letter to its stockholders.Cutaneous Squamous Cell Carcinoma. Cutaneous squamous cell carcinoma (SCC), non-melanoma skin cancer, is one of the most common cancers with an estimated incidence of more than 1,000,000 cases in the U.S. each year. Approximately 20% of patients have high-risk factors based on tumor depth, histology, anatomic location, and/or immunosuppression.Castle Biosciences, Inc. 820 S. Friendswood Drive, Suite 201 Friendswood, Texas 77546 (866) 788-9007 (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service) Copies to: Thomas A. Coll, Esq. Karen E. Deschaine, Esq. Cooley LLP 4401 Eastgate MallAcquisition will expand Castle’s estimated U.S. TAM by approximately $1 billion Castle executive management to host conference call and webcast today at 7:30 a.m. ET FRIENDSWOOD, Texas--(BUSINESS WIRE)—Oct. 19, 2021-- Castle Biosciences, Inc. (Nasdaq: CSTL), applying innovative diagnostics to transform disease management and …Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ...Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, Castle Biosciences, Inc. (the “Registrant”) is filing this Registration Statement on Form S-1 (this “Registration Statement”) with the Securities and Exchange Commission (the “Commission”). This Registration Statement relates to the public offering of securities ...you invested in castle biosciences, inc. and it’s time to vote! this is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on may 25, 2023 at 10:00 a.m. edt at the omni william penn hotel, 530 william penn place, pittsburgh, pennsylvania 15219. ...On June 6, 2022, the Reporting Person transferred 130,000 shares of Castle Biosciences, Inc. common stock that was previously not reported to the DJM Grantor Retained Annuity Trust No. 4 of which the Reporting Person is trustee and beneficiary. 4. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse …

Castle Biosciences, Inc. (the ‘‘Company,’’ “we,” “us” or “our”) was incorporated in the state of Delaware on September 12, 2007. We are a commercial-stage diagnostics company focused on providing physicians and their patients with personalized, clinically actionable information to inform treatment decisions and improve ...Castle Biosciences Reports Third Quarter 2023 Results. Published: Nov 02, 2023. Q3 2023 revenue increased 66% over Q3 2022 to $61 million. Q3 2023 total test reports increased 52% over Q3 2022. Raising full year 2023 revenue guidance to at least $200 million from at least $180 million. Conference call and webcast today at 4:30 p.m. ET.Nov 2, 2023 · Castle Biosciences Reports Third Quarter 2023 Results. Published: Nov 02, 2023. Q3 2023 revenue increased 66% over Q3 2022 to $61 million. Q3 2023 total test reports increased 52% over Q3 2022. Raising full year 2023 revenue guidance to at least $200 million from at least $180 million. Conference call and webcast today at 4:30 p.m. ET. Instagram:https://instagram. documentary on ozempicqqqaicf etf1776 quarter worth If you're a new customer to Castle Biosciences, please call us when ordering a test. If a returning customer, you can use the requisition form. Skip to content. COVID-19 Response. Customer Service: 866-788-9007. CLINICIAN PORTAL. ORDER TEST. COVID-19 Response. ORDER TEST. Customer Service: 866-788-9007.FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Centers for ... airproducts stocksolarcity stock price Castle Biosciences. Manufacturing · Texas, United States · 342 Employees. Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. Castle Biosciences is headquartered in Friendswood, Texas with operations in Phoenix, Arizona. Read More. View Company Info for Free According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ... betterment sec Nov 4, 2023 · Castle Biosciences, Inc. 19.85. +0.47. +2.43%. Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences ... Deciding the frequency and intensity of follow-up and surveillance. DecisionDx-SCC is performed on formalin-fixed, paraffin embedded (FFPE) primary tumor tissue from either a biopsy or excision. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.23 May 2023 ... Castle Biosciences Inc., which uses spatial biology and artificial intelligence driven-image analysis, will use the Nova Place lab for analyzing ...